Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07046000 · ClinicalTrials.gov registry record

MRI Evaluation of Graft Maturation Following ACL Reconstruction

A clinical trial, sponsored by Skye Biologics Holdings.

Not yet
Registry status
10
Enrollment target

NCT07046000: Clinical Trial study, sponsored by Skye Biologics Holdings.

NCT07046000 is a clinical trial that has not yet begun recruiting, run by Skye Biologics Holdings. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07046000 has not yet begun recruiting, sponsored by Skye Biologics Holdings.

NOT YET RECRUITING
Registry status
10 participants
Enrollment target

Study Summary

Post-surgical ACL Graft maturation will be assessed at 4.5, 6, 7.5, 9, 10.5, and 12 months with MRI.

Primary Outcome

The signal to noise ratio will be calculated at the proximal, mid-substance, and distal positions of the graft

Interventions

  • DIAGNOSTIC_TEST MRI

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2026-08-01
Est. Completion 2028-02
Skye Biologics Holdings

3 total trials

What is known before NCT07046000 opens enrollment

NCT07046000 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which MRI is the first listed.

NCT07046000 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07046000 about?

NCT07046000 is a clinical study titled "MRI Evaluation of Graft Maturation Following ACL Reconstruction". Post-surgical ACL Graft maturation will be assessed at 4.5, 6, 7.5, 9, 10.5, and 12 months with MRI.

What is the current status of trial NCT07046000?

This trial is currently not yet recruiting. The enrollment target is 10 participants. The study started on 2026-08-01. Estimated completion is 2028-02.

What interventions are being tested in trial NCT07046000?

The interventions under investigation include: MRI (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT07046000?

This trial is sponsored by Skye Biologics Holdings, which has 3 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07046000, the US trial registry maintained by the National Library of Medicine. NCT07046000 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.